- Home
- TSHA vs MMI Comparison
TSHA vs MMI Comparison
Compare TSHA & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSHA | MMI |
|---|---|---|
| Founded | 2019 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TSHA | MMI |
|---|---|---|
| Price | $4.46 | $26.15 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 9 | 2 |
| Target Price | $10.56 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.1M | 299.1K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | ★ 1.89% |
| EPS Growth | 62.50 | ★ 84.38 |
| EPS | N/A | ★ N/A |
| Revenue | $8,333,000.00 | ★ $719,700,000.00 |
| Revenue This Year | N/A | $14.04 |
| Revenue Next Year | N/A | $11.35 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $24.43 |
| 52 Week High | $6.02 | $36.70 |
Technical Indicators
Market Signals| Indicator | TSHA | MMI |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 47.12 |
| Support Level | $4.41 | $24.89 |
| Resistance Level | $5.16 | $27.32 |
| Average True Range (ATR) | 0.20 | 0.84 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 20.13 | 52.76 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.